ArticleJournal of thoracic disease2025
Establishment of a prognostic nomogram for evaluating non-adjuvant therapy in patients with stage I to III esophageal cancer: a population-based study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: According to reports from China, esophageal cancer ranked sixth in terms of morbidity and accounted for 6.26% of all cancer cases in China. This study aimed to establish an effective prognostic nomogram for non-adjuvant therapy in patients with stage I to III esophageal cancer. Methods: We took up cases from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database and used R language software to perform Kaplan-Meier survival curve and multivariate Cox regression analysis. Furthermore, we established the nomogram for non-adjuvant therapy patients with stage I to III esophageal cancer to predict 3- and 5-year esophageal cancer-specific survival rate. The prognostic ability of the nomogram was assessed using the C-index, area under the receiver operating characteristic (ROC) curve, and calibration chart. Results: The esophageal cancer-specific survival rate of cancer in the lower third of the esophagus was significantly higher than that of cancers in the upper-third of the esophagus as per the Kaplan-Meier curve. Based on the multivariate Cox regression analysis, sub variables such as advanced age, stage II and III, squamous cell carcinoma, moderately differentiated (grade II), poorly differentiated (grade III), and undifferentiated (grade IV) cancer significantly increased risk of prognosis in all patients. With a total of 150 points in the nomogram, the 3- and 5-year esophageal cancer-specific survival rates were 50% and 40% respectively. The value of C-index of this model was 0.851 and the value of the area under receiver operating curve projected 1-, 3-, and 5-year esophageal cancer-specific survival rates of 0.884, 0.874, and 0.856, respectively. Conclusions: The established nomogram had good prediction ability for non-adjuvant therapy patients with stage I to III esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.